Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Crispr Therapeutics stock
Learn how to easily invest in Crispr Therapeutics stock.
Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Crispr Therapeutics employs 473 staff and has a trailing 12-month revenue of around $14.1 million.
How to buy Crispr Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CRSP. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
Crispr Therapeutics stock price (NASDAQ: CRSP)Use our graph to track the performance of CRSP stocks over time.
Crispr Therapeutics shares at a glance
|Latest market close||$50.47|
|52-week range||$38.94 - $86.95|
|50-day moving average||$50.22|
|200-day moving average||$60.41|
|Wall St. target price||$95.30|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$3.76|
Buy Crispr Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Crispr Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Crispr Therapeutics price performance over time
|1 week (2023-01-20)||1.73%|
|1 month (2022-12-27)||23.07%|
|3 months (2022-10-27)||-3.61%|
|6 months (2022-07-27)||-36.06%|
|1 year (2022-01-27)||-14.11%|
|2 years (2021-01-27)||-69.22%|
|3 years (2020-01-27)||53.59|
|5 years (2018-01-26)||27.93%|
Is Crispr Therapeutics stock undervalued or overvalued?
Valuing Crispr Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Crispr Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Crispr Therapeutics's P/E ratio
Crispr Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Crispr Therapeutics shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Crispr Therapeutics financials
|Revenue TTM||$14.1 million|
|Gross profit TTM||$476.3 million|
|Return on assets TTM||-16.6%|
|Return on equity TTM||-30.48%|
|Market capitalisation||$3.9 billion|
TTM: trailing 12 months
Crispr Therapeutics share dividends
We're not expecting Crispr Therapeutics to pay a dividend over the next 12 months.
Have Crispr Therapeutics's shares ever split?
Crispr Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your Crispr Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Crispr Therapeutics shares which in turn could have impacted Crispr Therapeutics's share price.
Crispr Therapeutics share price volatility
Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $38.94 up to $86.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.5982. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Crispr Therapeutics overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc.
Crispr Therapeutics in the news
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Frequently asked questionsWhat percentage of Crispr Therapeutics is owned by insiders or institutions?
Currently 1.467% of Crispr Therapeutics shares are held by insiders and 69.002% by institutions. How many people work for Crispr Therapeutics?
Latest data suggests 473 work at Crispr Therapeutics. When does the fiscal year end for Crispr Therapeutics?
Crispr Therapeutics's fiscal year ends in December. Where is Crispr Therapeutics based?
Crispr Therapeutics's address is: Baarerstrasse 14, Zug, Switzerland, 6300 What is Crispr Therapeutics's ISIN number?
Crispr Therapeutics's international securities identification number is: CH0334081137 What is Crispr Therapeutics's CUSIP number?
Crispr Therapeutics's Committee on Uniform Securities Identification Procedures number is: H17182108
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert